세포 치료 시장 분석 및 예측(-2035년) : 유형, 제품, 서비스, 기술, 구성 요소, 용도, 프로세스, 최종 사용자, 솔루션, 단계

The global Cell Therapy Market is projected to grow from $13.9 billion in 2025 to $61.4 billion by 2035, at a compound annual growth rate (CAGR) of 15.9%. The cell therapy market is driven by expanding adoption of advanced cellular therapies and increasing regulatory support. According to the U.S. Food and Drug Administration (FDA), in June 2025 the agency eliminated the Risk Evaluation and Mitigation Strategy (REMS) requirements for all approved BCMA- and CD19-directed CAR-T cell therapies, reflecting growing confidence in the safety and clinical use of these treatments. The streamlined regulatory pathway is expected to improve patient access and support broader adoption of cell therapies.

The Type segment of the Cell Therapy Market includes autologous, allogeneic, xenogeneic, syngeneic, and others. Among these, autologous cell therapy holds a significant market share due to its advantages, including reduced risk of immune rejection and improved patient compatibility. It is widely used in personalized medicine, oncology, and regenerative medicine applications. Allogeneic cell therapy is witnessing rapid growth due to its scalability, availability of donor-derived cells, and potential for developing off-the-shelf therapies. Xenogeneic and syngeneic approaches are primarily used in specialized research and therapeutic development applications. Increasing advancements in cell engineering, gene editing, and manufacturing technologies are further supporting the expansion of cell therapy solutions.

The End User segment of the Cell Therapy Market includes hospitals and clinics, academic and research institutes, biopharmaceutical companies, and others. Biopharmaceutical companies represent a major end-user segment due to their significant investments in developing cell-based therapies, conducting clinical trials, and commercializing advanced treatments. Hospitals and clinics are increasingly adopting cell therapies for oncology, regenerative medicine, and chronic disease management applications. Academic and research institutes contribute to market growth through innovations in cell biology, disease modeling, and therapeutic discovery. The increasing number of clinical trials, regulatory approvals, and collaborations between research organizations and industry players are further driving adoption across end-user segments.

Geographical Overview

North America held the largest share of the global cell therapy market in 2025, driven by its advanced biotechnology ecosystem, robust clinical research infrastructure, and significant investments in regenerative medicine. The region is home to leading biotechnology and pharmaceutical companies developing autologous and allogeneic cell therapies for oncology, hematological disorders, autoimmune diseases, and rare genetic conditions. Strong government funding, favorable regulatory pathways for advanced therapy medicinal products (ATMPs), and a high number of ongoing clinical trials have accelerated the commercialization of innovative cell therapies. Additionally, the presence of specialized manufacturing facilities, contract development and manufacturing organizations (CDMOs), and increasing adoption of CAR-T cell therapies continue to reinforce North America's leadership in the global cell therapy market.

Asia Pacific is expected to witness the highest growth in the cell therapy market due to expanding biotechnology and biopharmaceutical industries, increasing investments in regenerative medicine, and growing government support for advanced therapeutic research. Countries such as China, Japan, South Korea, India, and Singapore are strengthening their cell therapy capabilities through national research initiatives, favorable regulatory reforms, and expanding GMP-compliant manufacturing facilities. Rising prevalence of cancer and chronic diseases, increasing clinical trial activity, and growing adoption of personalized medicine are further driving market expansion. Moreover, strategic collaborations between biotechnology companies, academic institutions, and healthcare providers, coupled with improving healthcare infrastructure and rising investments in cell processing technologies, are expected to position Asia Pacific as the fastest-growing regional market during the forecast period.

Key Trends and Drivers

Increasing Adoption of Next-Generation Cell Therapies and Allogeneic Platforms:

The Cell Therapy Market is witnessing a strong trend toward the development of next-generation cell therapies, including allogeneic off-the-shelf treatments, engineered immune cell therapies, and gene-modified cell products. Companies are increasingly focusing on improving scalability, manufacturing efficiency, and treatment accessibility by overcoming limitations associated with traditional autologous therapies. Advances in technologies such as CAR-T cell engineering, induced pluripotent stem cells (iPSCs), and gene editing are expanding applications beyond oncology into autoimmune disorders, cardiovascular diseases, and regenerative medicine. Additionally, innovations in automated cell processing, cryopreservation, and closed-system manufacturing are enhancing the reliability and commercial potential of cell-based therapies.

Growing Demand for Advanced Cancer Treatments and Regenerative Medicine:

The rising prevalence of cancer and the increasing demand for advanced regenerative therapies are major drivers of the Cell Therapy Market. Cell-based treatments, particularly CAR-T therapies, have demonstrated significant potential in treating hematological malignancies, creating strong demand for innovative oncology solutions. Furthermore, increasing research into stem cell therapies and regenerative approaches is expanding applications across neurological disorders, tissue repair, and immune-related diseases. Growing investments from pharmaceutical companies, biotechnology firms, and research institutions, along with increasing clinical trials and regulatory approvals for cell-based products, are accelerating market growth. The expansion of personalized medicine initiatives is further supporting the adoption of cell therapy solutions worldwide.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Process
• 2.7 Key Market Highlights by Services
• 2.8 Key Market Highlights by Component
• 2.9 Key Market Highlights by Stage
• 2.10 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Autologous
  • 4.1.2 Allogeneic
  • 4.1.3 Xenogeneic
  • 4.1.4 Syngeneic
  • 4.1.5 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Stem Cell Therapy
  • 4.2.2 Non-Stem Cell Therapy
  • 4.2.3 Others
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Somatic Cell Technology
  • 4.3.2 Gene Editing Technology
  • 4.3.3 Cell Immortalization Technology
  • 4.3.4 Cell Plasticity Technology
  • 4.3.5 Others
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Oncology
  • 4.4.2 Cardiovascular Diseases
  • 4.4.3 Musculoskeletal Disorders
  • 4.4.4 Neurological Disorders
  • 4.4.5 Dermatology
  • 4.4.6 Autoimmune Disorders
  • 4.4.7 Infectious Diseases
  • 4.4.8 Others
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals and Clinics
  • 4.5.2 Academic and Research Institutes
  • 4.5.3 Biopharmaceutical Companies
  • 4.5.4 Others
• 4.6 Market Size & Forecast by Process (2020-2035)
  • 4.6.1 Cell Expansion
  • 4.6.2 Cell Isolation
  • 4.6.3 Cell Cryopreservation
  • 4.6.4 Cell Characterization
  • 4.6.5 Others
• 4.7 Market Size & Forecast by Services (2020-2035)
  • 4.7.1 Contract Manufacturing
  • 4.7.2 Cell Processing
  • 4.7.3 Cell Banking
  • 4.7.4 Others
• 4.8 Market Size & Forecast by Component (2020-2035)
  • 4.8.1 Cell Lines
  • 4.8.2 Reagents and Media
  • 4.8.3 Consumables
  • 4.8.4 Equipment
  • 4.8.5 Others
• 4.9 Market Size & Forecast by Stage (2020-2035)
  • 4.9.1 Preclinical
  • 4.9.2 Phase I
  • 4.9.3 Phase II
  • 4.9.4 Phase III
  • 4.9.5 Commercialized
  • 4.9.6 Others
• 4.10 Market Size & Forecast by Solutions (2020-2035)
  • 4.10.1 Regenerative Medicine
  • 4.10.2 Immunotherapy
  • 4.10.3 Gene Therapy
  • 4.10.4 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Process
    • 5.2.1.7 Services
    • 5.2.1.8 Component
    • 5.2.1.9 Stage
    • 5.2.1.10 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Process
    • 5.2.2.7 Services
    • 5.2.2.8 Component
    • 5.2.2.9 Stage
    • 5.2.2.10 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Process
    • 5.2.3.7 Services
    • 5.2.3.8 Component
    • 5.2.3.9 Stage
    • 5.2.3.10 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Process
    • 5.3.1.7 Services
    • 5.3.1.8 Component
    • 5.3.1.9 Stage
    • 5.3.1.10 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Process
    • 5.3.2.7 Services
    • 5.3.2.8 Component
    • 5.3.2.9 Stage
    • 5.3.2.10 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Process
    • 5.3.3.7 Services
    • 5.3.3.8 Component
    • 5.3.3.9 Stage
    • 5.3.3.10 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Process
    • 5.4.1.7 Services
    • 5.4.1.8 Component
    • 5.4.1.9 Stage
    • 5.4.1.10 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Process
    • 5.4.2.7 Services
    • 5.4.2.8 Component
    • 5.4.2.9 Stage
    • 5.4.2.10 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Process
    • 5.4.3.7 Services
    • 5.4.3.8 Component
    • 5.4.3.9 Stage
    • 5.4.3.10 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Process
    • 5.4.4.7 Services
    • 5.4.4.8 Component
    • 5.4.4.9 Stage
    • 5.4.4.10 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Process
    • 5.4.5.7 Services
    • 5.4.5.8 Component
    • 5.4.5.9 Stage
    • 5.4.5.10 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Process
    • 5.4.6.7 Services
    • 5.4.6.8 Component
    • 5.4.6.9 Stage
    • 5.4.6.10 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Process
    • 5.4.7.7 Services
    • 5.4.7.8 Component
    • 5.4.7.9 Stage
    • 5.4.7.10 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Process
    • 5.5.1.7 Services
    • 5.5.1.8 Component
    • 5.5.1.9 Stage
    • 5.5.1.10 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Process
    • 5.5.2.7 Services
    • 5.5.2.8 Component
    • 5.5.2.9 Stage
    • 5.5.2.10 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Process
    • 5.5.3.7 Services
    • 5.5.3.8 Component
    • 5.5.3.9 Stage
    • 5.5.3.10 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Process
    • 5.5.4.7 Services
    • 5.5.4.8 Component
    • 5.5.4.9 Stage
    • 5.5.4.10 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Process
    • 5.5.5.7 Services
    • 5.5.5.8 Component
    • 5.5.5.9 Stage
    • 5.5.5.10 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Process
    • 5.5.6.7 Services
    • 5.5.6.8 Component
    • 5.5.6.9 Stage
    • 5.5.6.10 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Process
    • 5.6.1.7 Services
    • 5.6.1.8 Component
    • 5.6.1.9 Stage
    • 5.6.1.10 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Process
    • 5.6.2.7 Services
    • 5.6.2.8 Component
    • 5.6.2.9 Stage
    • 5.6.2.10 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Process
    • 5.6.3.7 Services
    • 5.6.3.8 Component
    • 5.6.3.9 Stage
    • 5.6.3.10 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Process
    • 5.6.4.7 Services
    • 5.6.4.8 Component
    • 5.6.4.9 Stage
    • 5.6.4.10 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Process
    • 5.6.5.7 Services
    • 5.6.5.8 Component
    • 5.6.5.9 Stage
    • 5.6.5.10 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Novartis
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Gilead Sciences
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Bristol Myers Squibb
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Bluebird Bio
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Fate Therapeutics
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Sangamo Therapeutics
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Kite Pharma
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Juno Therapeutics
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Adaptimmune Therapeutics
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Celgene
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Allogene Therapeutics
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 CRISPR Therapeutics
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Editas Medicine
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Intellia Therapeutics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Cellectis
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Bellicum Pharmaceuticals
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Atara Biotherapeutics
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Vericel Corporation
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Athersys
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Mesoblast
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us